Supplementary Financial Information (FY2025 Third Quarter Financial Results)

Summary of Financial Results

For the cumulative third quarter of FY2025, revenue amounted to 1,533.5 billion yen, representing a 12.1% increase year-over-year. Operating income was 233.8 billion yen, down 5.9% year-over-year; however, core operating income increased by 8.8% year-over-year to 249.2 billion yen, indicating an improvement in recurring profitability. Net income attributable to owners of parent rose 4.2% year-over-year to 217.4 billion yen. The overseas sales ratio remained high at 70.2%. Sales of key global products, including the anticancer agent trastuzumab deruxtecan (Enhertu) and Daturway, performed well, particularly with strong growth in the U.S. market.

Financial Position and Cash Flow

As of the end of December 2025, total assets were 3,821.8 billion yen, an increase of 365.7 billion yen compared to the end of the previous fiscal year. Current assets stood at 2,095.2 billion yen and non-current assets at 1,726.6 billion yen. Interest-bearing debt increased by 195.3 billion yen to 351.2 billion yen year-over-year, reducing net cash to 327.9 billion yen. Cash flow from operating activities was positive 51.7 billion yen, cash flow from investing activities was negative 159.7 billion yen, and cash flow from financing activities was positive 0.4 billion yen. Free cash flow totaled negative 108.0 billion yen.